Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-1004-1239 in progressive multiple sclerosis
NL-OMON60959Phase 2Recruiting
- Sponsor
- Idorsia
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in multiple sclerosis (MS) comparing ACT-1004-1239 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 24 in myelin water fraction of the corpus callosum. Started Mar 2026; status: recruiting.
02
Drugs
ACT-1004-1239
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON60959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60959.